Charles River Laboratories (CRL) Tops Q2 EPS by 10c; Bumps Outlook Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Charles River Labs (CRL) PT Raised to $100 at Jefferies
August 4, 2016 10:50 AM EDTJefferies analyst raised his price target on Buy-rated Charles River Labs (NYSE: CRL) to $100.00 (from $94.00) following recent earnings.
commented, "CRL displayed continued strength across all segments. Integration of WIL is underway and should lead to margin leverage from the $17-20M cost synergies. CRL is the pre-clinical CRO "category killer" and continues to drive share gains and revenue growth through comprehensive offerings and a focus on high quality science with benefits to utilization, price, and margin."
The analyst had 4 Key Insights:
1) DSA Outperforms in 1st Quarter with WIL. DSA revenue grew... More
Charles River Labs (CRL) PT, Estimates Raised at Evercore ISI
August 3, 2016 11:08 AM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Charles River Labs (NYSE: CRL) to $91.50 (from $83.50) but maintained a Hold rating.
Muken commented, "Charles Rivers epic nine quarter run continued (core growth in HSD) as biopharma end market strength remains the main story. Strong demand across the... More
